HR5160Referred to Committee

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-09-04
Introduced
21
Cosponsors
HR
ⓘ
Type

Sponsor

Christopher H. Smith
Christopher H. Smith
Republican · NJ · Representative
Votes with party: 96.5% (548 recorded votes)

Full profile: /officials/S000522

Source: Congress.gov · FEC

Cosponsors (21)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.

2026-05-21

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

This bill would reauthorize federal funding and oversight for stem cell research and therapies, allowing scientists to continue studying how stem cells might treat diseases like Parkinson's, diabetes, and spinal cord injuries. The legislation affects medical researchers, pharmaceutical companies developing new treatments, and patients who could potentially benefit from stem cell-based therapies in the future. It essentially renews the government's commitment to this area of medical science by providing the legal authority and funding mechanisms needed to keep these research programs running.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 5160 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 5160 To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES September 4, 2025 Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms. Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Stem Cell Therapeutic and Research Reauthorization Act of 2025''. SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM. Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended-- (1) by striking ``appropriated $31,009,000'' and inserting the following: ``appropriated-- ``(1) $31,009,000''; (2) in paragraph (1), as so inserted, by striking the period at the end and inserting ``; and''; and (3) by adding at the end the following: ``(2) $33,009,000 for each of fiscal years 2027 through 2031.''. SEC. 3. CORD BLOOD INVENTORY. Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking ``2026'' and inserting ``2031''. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.